Dose Escalation Study of Kylo-0603 in Healthy Subjects
Status:
COMPLETED
Trial end date:
2024-08-16
Target enrollment:
Participant gender:
Summary
This clinical trial is the first-in-human study of Kylo-0603. The purpose of this randomized, double-blind, placebo-controlled phase 1 study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and effect of food of Kylo-0603 in healthy Chinese adult subjects.